Jiawei Baitouweng Decoction affects intestinal mucosal tight junction proteins in rats with ulcerative colitis through p38 MAPK-MLCK signaling pathway.
10.19540/j.cnki.cjcmm.20210604.401
- Author:
Pei-Pei ZHANG
1
;
Xin YANG
2
;
Guo-Qiang LIANG
3
;
Hui-Ping ZHU
4
;
Hui ZHU
4
;
Meng WANG
1
;
Hong-Wen SUN
4
Author Information
1. Nanjing University of Chinese Medicine Nanjing 210023, China Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine Suzhou 215008, China.
2. Nanjing University of Chinese Medicine Nanjing 210023, China the Affiliated Suzhou Science & Technology Town Hospital of Nanjing Medical University Suzhou 215000, China.
3. Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine Suzhou 215008, China Suzhou Academy of Wumen Chinese Medicine Suzhou 215008, China.
4. Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine Suzhou 215008, China.
- Publication Type:Journal Article
- Keywords:
Jiawei Baitouweng Tang;
MLCK;
ZO-1;
claudin-1;
endotoxin;
occludin;
p38 MAPK;
ulcerative colitis
- MeSH:
Animals;
Colitis, Ulcerative/genetics*;
Disease Models, Animal;
Intestinal Mucosa;
Male;
Rats;
Rats, Sprague-Dawley;
Signal Transduction;
Tight Junction Proteins/genetics*;
p38 Mitogen-Activated Protein Kinases/genetics*
- From:
China Journal of Chinese Materia Medica
2021;46(21):5719-5726
- CountryChina
- Language:Chinese
-
Abstract:
The aim of this paper was to explore the effect and mechanism of Jiawei Baitouweng Decoction(JWBTW) against ulcerative colitis(UC) from the perspective of intestinal mucosal tight junction proteins. From 60 SPF-grade male SD rats, 10 were randomly selected as the blank control, and the remaining 50 were treated with 3% dextran sodium sulfate(DSS) solution to induce UC and then randomized into the model group, mesalazine group, and low-, medium-, and high-dose JWBTW( L-JWBTW, M-JWBTW and H-JWBTW) groups, with 10 rats in each group. After successive medication for 14 days, the rat general conditions like body weight and stool were observed and the disease activity index(DAI) was calculated. The pathological changes in colon tissue was observed under a microscope for injury severity scoring and histopathological scoring. The serum endotoxin content was determined by limulus assay, followed by the measurement of protein expression levels of ZO-1, occludin, claudin-1, p38 MAPK, MLCK, MLC2 and p-MLC in colon tissue by Western blot. The results showed that compared with the blank group, the model group exhibited significantly reduced body weight, elevated DAI, injury severity and histopathological scores and serum endotoxin content, up-regulated protein expression levels of p38 MAPK, MLCK, MLC2 and p-MLC, and down-regulated ZO-1, occludin and claudin-1. Compared with the model group,mesalazine and JWBTW at each dose obviously increased the body weight, lowered the DAI, injury severity and histopathological scores and serum endotoxin content, down-regulated the protein expression levels of p38 MAPK, MLCK, MLC2 and p-MLC, and up-regulated the ZO-1, occludin and claudin-1, with the most obvious changes noticed in the H-JWBTW group. All these have indicated that JWBTW exerts the therapeutic effect against UC by inhibiting the activation of p38 MAPK/MLCK pathway, reversing the protein expression levels of occludin, claudin-1 and ZO-1, decreasing the serum endotoxin content, promoting the repair of intestinal mucosal mechanical barrier, maintaining the integrity of tight junctions, and reducing the permeability of intestinal mucosa.
